¤ Home » Clinical Trials » Ongoing Clinical Trials

Ongoing Clinical Trials

EliLilly

Protocol: AZ D5010C0009

Status: Active

A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study).

Read More




RAmP

Protocol: RAmP F-AV-45-A25

Status: Recruiting

Registry of Amyloid Positive Patients for Alzheimer’s Disease Drug Research Trials (RAmP).

Read More




Biogen 103

Protocol: Biogen 221AD103

Status: Active, but not recruiting participants

A Randomized, Double-Blind, Placebo-controlled Multi Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in subjects With Prodromal or Mild Alzheimer’s Disease.

Read More




Biogen 301

Protocol: Biogen 221AD301

Status: Recruiting

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease.

Read More




BAC 02

Protocol: BAC-02

Status: Recruiting

A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate the Efficacy and Safety of BAC in Patient with Alzheimer’s disease or Vascular Dementia.

Read More




Eisai BAN2401

Protocol: Eisai BAN2401-G000-201

Status: Active

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease.

Read More




Eisai E2006

Protocol: Eisai E2006-G000-202

Status: Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer’s Disease Dementia.

Read More




Eisai E2609

Protocol: Eisai E2609-G000-302

Status: Enrollment Yet to start

A Placebo-Controlled, Double –Blind, Parallel Group, 24-Month Study to Evaluvate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease.

Read More




17X-MC-LLCF

Protocol: 17X-MC-LLCF

Status: Recruiting

Effect of LY3202626 on Alzheimer’s Disease Progression as Measured by Cerebral 1451 Tau-PET in Mild Alzheimer’s Disease Dementia.

Read More




DAYBREAK-ALZ

Protocol: 18D-MC-AZET

Status: Recruiting

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s disease Dementia (The DAYBREAK Study).

Read More




18D-MC-AZFD

Protocol: 18D-MC-AZFD

Status: Enrollment Yet to start

A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study).

Read More




Ideas

Status: Recruiting

A The Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study. Will establish an open-label, longitudinal cohort study to assess the impact of amyloid PET on patient outcomes.

Read More




Roche

Protocol: BN29552

Status: Recruiting

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

Read More




Suven

Protocol: SUVEN-CTP2S1502HT6

Status: Recruiting

A Phase 2A Multicentre, Randomized, Double-Blind, Parallel Group, 23-Week, Placebo-Controlled Study of 50mg and 100mg of SUVN-502 in subjects with moderate Alzheimer’s Disease Currently treated with Donepezil hydrochloride and Mementin hydrochloride.

Read More